Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy
- PMID: 29025882
- DOI: 10.1183/13993003.01465-2017
Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy
Conflict of interest statement
Conflict of interest: None declared.
Comment on
-
Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.Eur Respir J. 2017 Oct 12;50(4):1700711. doi: 10.1183/13993003.00711-2017. Print 2017 Oct. Eur Respir J. 2017. PMID: 29025888 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources